Autonomic Blockade for High Blood Pressure

LE
EC
CS
IB
AD
AG
Overseen ByAlfredo Gamboa, M.D.
Age: 18+
Sex: Any
Trial Phase: Phase 1
Sponsor: Vanderbilt University
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to explore how the body's nervous system might affect high blood pressure. Researchers are testing whether trimethaphan, a type of autonomic blockade, can help by blocking nerve signals that cause blood vessels to tighten. Participants will receive either trimethaphan or a comparison treatment with nitroglycerin to observe how these drugs influence blood pressure. Individuals with high blood pressure (systolic BP ≥140 mm Hg or diastolic BP ≥ 90 mm Hg) or normal blood pressure, who do not have chronic diseases like diabetes or heart disease, might be suitable for this study. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this treatment.

Will I have to stop taking my current medications?

The trial requires that participants do not take any medications that affect autonomic functions, so you may need to stop certain medications if they influence these functions.

Is there any evidence suggesting that this trial's treatments are likely to be safe?

Previous studies have shown that nitroglycerin helps with heart-related issues like chest pain and high blood pressure by relaxing blood vessels, which can lower blood pressure. However, it may cause side effects such as headaches or low blood pressure if not monitored carefully. While generally well-tolerated, individuals with certain head injuries should avoid it due to its effects on blood flow.

Research shows that trimethaphan is used to quickly lower blood pressure in emergencies. It is effective but requires careful use in individuals with certain health conditions, like heart or liver disease. Some may experience a drop in blood pressure or dizziness. Trimethaphan has been studied for its ability to lower blood pressure without increasing blood flow to the brain, which can be beneficial in specific medical situations.

Overall, both treatments manage blood pressure, but like any medication, they can have side effects that require careful monitoring.12345

Why are researchers excited about this trial's treatments?

Unlike the standard treatments for high blood pressure, like ACE inhibitors or beta-blockers, trimethaphan works by inducing autonomic blockade. This means it directly interrupts nerve signals that contribute to elevated blood pressure, offering a different mechanism of action compared to typical medications. Researchers are excited about trimethaphan because it is administered via continuous intravenous infusion, allowing for precise control over its effects. Additionally, its rapid action could offer quicker results in reducing blood pressure, which is particularly promising for managing acute situations.

What evidence suggests that this trial's treatments could be effective for high blood pressure?

Research has shown that trimethaphan, one of the treatments in this trial, effectively lowers blood pressure quickly. It blocks specific nerve signals that cause blood vessels to tighten. Studies indicate that it reduces blood pressure rapidly and consistently without causing it to drop too low, making it useful for managing high blood pressure during surgeries or emergencies. Trimethaphan has been used safely without causing serious side effects, such as a sudden increase in blood pressure or irregular heartbeats. Another treatment arm in this trial involves administering nitroglycerin sublingually to assess its effects on blood pressure.26789

Who Is on the Research Team?

Italo Biaggioni

Italo Biaggioni, MD

Principal Investigator

Vanderbilt University

Are You a Good Fit for This Trial?

This trial is for men and women aged 18-65 with high blood pressure, not on medication affecting autonomic functions, and without chronic diseases like diabetes or cardiovascular issues. Participants should be non-smokers, not pregnant, have a BMI under 40 kg/m2, and no strong family history of hypertension in lean normotensive subjects.

Inclusion Criteria

Subjects able and willing to provide informed consent
I have normal blood pressure or controlled high blood pressure.

Exclusion Criteria

My BMI is over 40.
I do not have a strong family history of high blood pressure, sleep apnea, and I am not a highly trained athlete.
I am a current smoker or have a history of heavy smoking.
See 2 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Baseline Assessment

Baseline measurements of splanchnic capacitance and blood pressure are taken

1 day
1 visit (in-person)

Treatment

Participants undergo autonomic blockade with trimethaphan and receive nitroglycerin to assess changes in splanchnic capacitance

1 day
1 visit (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • Nitroglycerin
  • Trimethaphan
Trial Overview The study aims to understand the role of abdominal veins (splanchnic capacitance) and sympathetic nervous system activity in hypertension by using Trimethaphan and Nitroglycerin to block autonomic nervous system signals temporarily.
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Group I: Study day with trimethaphanExperimental Treatment1 Intervention
Group II: Radionuclide Study day with nitroglycerinExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Vanderbilt University

Lead Sponsor

Trials
714
Recruited
6,143,000+

Citations

Quantification of glyceryl trinitrate effect through analysis of the ...The lowest dose of GTN caused a substantial fall of 4–6 mm Hg in estimated aortic pressure augmentation. This effect was apparent within 30 minutes of patch ...
Nitroglycerin Use in the Emergency Department: Current ...Because NTG provides both preload and afterload reduction, it is beneficial in AHF, especially for those who present with markedly elevated ...
Glyceryl Trinitrate - an overview | ScienceDirect TopicsThe efficacy was 100% in those given GTN and only 8% in those treated with placebo (P < 0.0001). Teatment with GTN also reduced the mean blood loss by nearly ...
Nitroglycerin use and adverse clinical outcomes in elderly ...Conclusions GTN use preceding PCI for ACS is associated with lower blood pressure and adverse clinical outcomes in elderly patients.
Effect of Glyceryl Trinitrate on Hemodynamics in Acute StrokeOver 7 days of treatment, GTN lowered mean BP by 2.9/2.1 mm Hg, MAP by 2.3 mm Hg, PP by 0.8 mm Hg, and increased HR by 1 bpm on average (Table ...
Nitroglycerin (oral route, sublingual route) - Side effects & ...Nitroglycerin is used to prevent angina (chest pain) caused by coronary artery disease. This medicine is also used to relieve an angina attack that is already ...
Nitroglycerin (medication)Nitroglycerin, also known as glyceryl trinitrate (GTN), is a vasodilator used for heart failure, high blood pressure, anal fissures, painful periods
Glyceryl Trinitrate Glyceryl trinitrate 5 mg/ml Sterile ...A starting dose of 25 microgram/min is recommended for the control of hypertension, or to produce hypotension during surgery. This may be increased by ...
Glyceryl Trinitrate - an overviewToxic effects of nitroglycerin are caused by vasodilatation and methemoglobinemia. Venous and arterial vasodilatation causes lowering of blood pressure leading ...
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security